Amylyx Pharmaceuticals, Inc. has disclosed a notable stock transaction involving one of its directors, George Milne. On October 5, 2026, Milne sold 30,000 shares of the company’s common stock. This sale is significant as it indicates the director's ongoing financial maneuvers within the company and reflects broader trends in the pharmaceutical industry.
Background
Amylyx Pharmaceuticals, Inc. operates in the pharmaceutical preparations sector, classified under SIC code 2834. The company is publicly traded on the Nasdaq under the ticker symbol AMLX. Recent filings indicate that Amylyx is categorized as a smaller reporting company and is incorporated in Delaware. The company has been active in the market with various filings, including Form 8-K and Form 10-Q, reflecting its ongoing business activities.
What the Filing Says
The recent filing, dated October 7, 2026, reveals that George Milne, a director at Amylyx, sold 30,000 shares at a weighted average price of $27.6968. The shares were sold as part of a Rule 10b5-1 trading plan adopted on April 28, 2026. Following this transaction, Milne retains ownership of 782,881 shares of the company.
Impact
This transaction may affect the perception of Amylyx Pharmaceuticals among investors and analysts, as director stock sales can sometimes signal changes in confidence or strategy within a company. However, Milne's continued ownership of a substantial number of shares suggests he still has a vested interest in the company's future performance.
What's Next
The filing does not say what happens next.